{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:25:43Z","timestamp":1790691943283,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":304,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The Coalition for Epidemic Preparedness Innovations (CEPI) was formed in the aftermath of the 2014\u20132015 Ebola outbreak in west Africa to support the development of vaccines that could improve the world\u2019s preparedness against outbreaks of epidemic infectious diseases. Since its launch in 2017, CEPI has mobilized more than US$750 million to support its mission to develop vaccines against agents such as Lassa virus, Middle East respiratory syndrome coronavirus, and Nipah virus, as well as several rapid-response vaccine platforms to accelerate response times to unexpected epidemic threats. CEPI has also played a leading role in fostering institutional partnerships between public- and private-sector organizations to optimize allocation of resources for vaccine development against its priority pathogens. CEPI\u2019s priorities include diversification of its current vaccine research and development investment portfolio to include additional pathogens, such as Rift Valley fever and chikungunya; establishment of technical and regulatory pathways for vaccine development across CEPI\u2019s portfolio; development of sustainable manufacturing solutions for vaccine candidates nearing completion of safety and immunogenicity testing in humans; and creation of investigational stockpiles of its vaccine candidates for use in emergency situations. This commentary provides an overview of the global health challenges CEPI was established to address and its achievements to date, and indicates priorities for funding and coordination in the coming years.<\/jats:p>","DOI":"10.1093\/epirev\/mxz012","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T19:38:18Z","timestamp":1570045098000},"page":"28-33","source":"Crossref","is-referenced-by-count":100,"title":["CEPI: Driving Progress Toward Epidemic Preparedness and Response"],"prefix":"10.1093","volume":"41","author":[{"given":"Dimitrios","family":"Gouglas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley A","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hatchett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,1]]},"reference":[{"issue":"suppl 5","key":"2021052713042730000_ref1","doi-asserted-by":"crossref","first-page":"S698","DOI":"10.1093\/infdis\/jiy213","article-title":"The economic and social burden of the 2014 Ebola outbreak in West Africa","volume":"218","author":"Huber","year":"2018","journal-title":"J Clin Infect Dis"},{"issue":"4","key":"2021052713042730000_ref2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nbt.3532","article-title":"Preparing for the next Zika","volume":"34","author":"Hoyt","year":"2016","journal-title":"Nat Biotech."},{"issue":"10009","key":"2021052713042730000_ref3","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/S0140-6736(15)00946-0","article-title":"Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM independent panel on the global response to Ebola","volume":"386","author":"Moon","year":"2015","journal-title":"Lancet"},{"issue":"33","key":"2021052713042730000_ref4","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/j.vaccine.2017.06.003","article-title":"The complexity and cost of vaccine manufacturing\u2014an overview","volume":"35","author":"Plotkin","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"2021052713042730000_ref5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJMp1506820","article-title":"Establishing a global vaccine-development fund","volume":"373","author":"Plotkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2021052713042730000_ref6","author":"World Bank","year":"7, 2019"},{"issue":"10068","key":"2021052713042730000_ref7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"2021052713042730000_ref8","volume-title":"An R&D Blueprint for Action to Prevent Epidemics: Plan of Action","author":"World Health Organization","year":"2016"},{"key":"2021052713042730000_ref9","volume-title":"Report of the United Nations Secretary-General\u2019s High-Level Panel on Access to Medicines","author":"High-Level Panel on Access to Health Technologies","year":"2016"},{"issue":"15","key":"2021052713042730000_ref10","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJMp1502918","article-title":"The next epidemic\u2014lessons from Ebola","volume":"372","author":"Gates","year":"2015","journal-title":"N Engl J Med"},{"key":"2021052713042730000_ref11","doi-asserted-by":"crossref","DOI":"10.17226\/21891","volume-title":"The Neglected Dimension of Global Security","author":"Commission on a Global Health Risk Framework for the Future; National Academy of Medicine, Secretariat","year":"2016"},{"key":"2021052713042730000_ref12","volume-title":"2018 Annual Review of Diseases Prioritized Under the Research and Development Blueprint","author":"World Health Organization","year":"2018"},{"key":"2021052713042730000_ref13","doi-asserted-by":"crossref","DOI":"10.1287\/inte.2019.1011","article-title":"Setting strategic objectives for the Coalition of Epidemic Preparedness Innovations: an exploratory decision analysis process","author":"Gouglas","year":"2019","journal-title":"INFORMS J Appl Anal"},{"issue":"7","key":"2021052713042730000_ref14","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMp1613577","article-title":"New vaccines against epidemic infectious diseases","volume":"376","author":"R\u00f8ttingen","year":"2017","journal-title":"N Engl J Med"},{"issue":"10066","key":"2021052713042730000_ref15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(17)30131-9","article-title":"CEPI\u2014a new global R&D organisation for epidemic preparedness and response","volume":"389","author":"Brende","year":"2017","journal-title":"Lancet"},{"key":"2021052713042730000_ref16","volume-title":"Coalition for Epidemic Preparedness Innovations Preliminary Business Plan 2017\u20132021","author":"Coalition for Epidemic Preparedness Innovations","year":"2016"},{"issue":"3\u20134","key":"2021052713042730000_ref17","first-page":"153","article-title":"Prioritizing investments in new vaccines against epidemic infectious diseases: a multi-criteria decision analysis","volume":"26","author":"Gouglas","year":"2019","journal-title":"JMCDA"},{"key":"2021052713042730000_ref18","author":"Coalition for Epidemic Preparedness Innovations"},{"issue":"35 Pt A","key":"2021052713042730000_ref19","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1016\/j.vaccine.2017.04.085","article-title":"Rapid development of vaccines against emerging pathogens: the replication-deficient simian adenovirus platform technology","volume":"35","author":"Gilbert","year":"2017","journal-title":"Vaccine"},{"issue":"14","key":"2021052713042730000_ref20","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jama.2018.0345","article-title":"Novel vaccine technologies: essential components of an adequate response to emerging viral diseases","volume":"319","author":"Graham","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"2021052713042730000_ref21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ddr.20180","article-title":"Building systems to support development of drugs for biodefense","volume":"68","author":"Taylor","year":"2007","journal-title":"Drug Dev Res."},{"key":"2021052713042730000_ref22","year":"26, 2019"},{"key":"2021052713042730000_ref23","year":"29, 2019"},{"key":"2021052713042730000_ref24","year":"23, 2019"},{"key":"2021052713042730000_ref25","year":"5, 2018"},{"key":"2021052713042730000_ref26","year":"10, 2019"},{"issue":"3","key":"2021052713042730000_ref27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057755","article-title":"Risk in vaccine research and development quantified","volume":"8","author":"Pronker","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"2021052713042730000_ref28","doi-asserted-by":"crossref","first-page":"e1386","DOI":"10.1016\/S2214-109X(18)30346-2","article-title":"Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study","volume":"6","author":"Gouglas","year":"2018","journal-title":"Lancet Glob Health"},{"key":"2021052713042730000_ref29","year":"19, 2019"},{"issue":"5","key":"2021052713042730000_ref30","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.1093\/infdis\/jiw291","article-title":"Meeting the challenge of epidemic chikungunya","volume":"214","author":"Morens","year":"2016","journal-title":"J Infect Dis"},{"key":"2021052713042730000_ref31","year":"19, 2018"},{"issue":"2","key":"2021052713042730000_ref32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3201\/eid1902.120941","article-title":"Rift Valley fever and a new paradigm of research and development for zoonotic disease control","volume":"19","author":"Dar","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"2021052713042730000_ref33","author":"Weber","year":"18, 2018.   19, 2018"}],"container-title":["Epidemiologic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/epirev\/advance-article-pdf\/doi\/10.1093\/epirev\/mxz012\/30339267\/mxz012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/epirev\/article-pdf\/41\/1\/28\/38324485\/epirev_41_1_28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/epirev\/article-pdf\/41\/1\/28\/38324485\/epirev_41_1_28.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T17:58:16Z","timestamp":1622138296000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/epirev\/article\/41\/1\/28\/5588068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,11,1]]},"published-print":{"date-parts":[[2019,1,31]]}},"URL":"https:\/\/doi.org\/10.1093\/epirev\/mxz012","relation":{},"ISSN":["1478-6729"],"issn-type":[{"value":"1478-6729","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019]]},"published":{"date-parts":[[2019]]}}}